Literature DB >> 26896348

Validation and Application of an LC-MS-MS Method for the Determination of Ceftizoxime in Human Serum and Urine.

Lu Wang1, Xin Zheng1, Wen Zhong1, Jia Chen1, Ji Jiang1, Pei Hu2.   

Abstract

Ceftizoxime sodium is a third-generation cephalosporin available for parenteral administration, which is mainly excreted through urine. A rapid and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS) method was developed and validated for the determination of ceftizoxime in human serum and urine. The samples were purified by protein precipitation and separated on an XTerra Phenyl column (4.6 × 50 mm, 5 µm). Electrospray ionization in the positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 383.9/227.0. The results revealed that the method had excellent selectivity. The linear range covered from 2.50 to 10,000 ng/mL in serum and from 0.500 to 50.0 µg/mL in urine, respectively. Intra-batch and inter-batch precisions (in terms of relative standard deviation) were all <15% and the accuracies (in terms of relative error) were within the range of ± 15%. The lower limit of quantification, stability and extraction recovery were also validated and satisfied the criteria of validation. Finally, the method was successfully applied to a pharmacokinetic study of Chinese elderly healthy subjects after intravenous administration. The Cmax values in serum were 34,721.3 ± 5,697.3 ng/mL. Serum concentrations declined with t1/2 of 2.57 ± 0.22 h.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26896348      PMCID: PMC4890441          DOI: 10.1093/chromsci/bmv243

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  11 in total

1.  [Identification of impurity peaks in the HPLC chromatogram by LC-MS and two-dimensional chromatographic correlation spectroscopy].

Authors:  Zhen-Zhen Chen; Dou-Sheng Zhang; Nan Wang; Fang Feng; Chang-Qin Hu
Journal:  Yao Xue Xue Bao       Date:  2012-04

2.  Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function.

Authors:  M M Neuhauser; P S McKinnon; E Hershberger; M J Rybak
Journal:  Pharmacotherapy       Date:  2000-05       Impact factor: 4.705

3.  Spectrophotometric determination of selected cephalosporins in drug formulations using flow injection analysis.

Authors:  I F Al-Momani
Journal:  J Pharm Biomed Anal       Date:  2001-07       Impact factor: 3.935

4.  Structural identification and characterization of impurities in ceftizoxime sodium.

Authors:  Ch Bharathi; Ch S Prasad; D Vijaya Bharathi; Rama Shankar; V Janardhana Rao; Ramesh Dandala; A Naidu
Journal:  J Pharm Biomed Anal       Date:  2006-09-06       Impact factor: 3.935

5.  Pharmacokinetics of ceftriaxone in carbontetrachloride-induced hepatopathic and uranyl nitrate-induced nephropathic goats following single dose intravenous administration.

Authors:  Tapas Kumar Sar; Tapan Kumar Mandal; Shymal Kumar Das; Animesh Kumar Chakraborty
Journal:  Drug Metab Lett       Date:  2008-01

6.  Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.

Authors:  F Vallée; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 7.  Determination of third-generation cephalosporins by high-performance liquid chromatography in connection with pharmacokinetic studies.

Authors:  F Péhourcq; C Jarry
Journal:  J Chromatogr A       Date:  1998-07-03       Impact factor: 4.759

8.  Phase I study of ceftizoxime, a new cephalosporin. Single-dose study.

Authors:  N Nakashima; K Suzuki; H Hashimoto; K Nishijima
Journal:  J Clin Pharmacol       Date:  1981-10       Impact factor: 3.126

9.  Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients.

Authors:  B Facca; B Frame; S Triesenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

10.  Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney.

Authors:  Lei Ci; Hiroyuki Kusuhara; Masashi Adachi; John D Schuetz; Kenji Takeuchi; Yuichi Sugiyama
Journal:  Mol Pharmacol       Date:  2007-03-07       Impact factor: 4.436

View more
  1 in total

Review 1.  FDA-Approved Oximes and Their Significance in Medicinal Chemistry.

Authors:  Jyothi Dhuguru; Eugene Zviagin; Rachid Skouta
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.